FDA Announces 2024 NYTS Data and PATH Webinar

Regulations by 2FIRSTS.ai
Dec.19.2024
FDA Announces 2024 NYTS Data and PATH Webinar
FDA releases 2024 NYTS data showing record low youth tobacco use, PATH webinar announcement. Join now for important findings.

On December 18th, the Food and Drug Administration (FDA) released the 2024 NYTS data research results and announced an upcoming webinar for the PATH (Population Assessment of Tobacco and Health) network.

 

Teen Tobacco Product Usage Rates are at Their Lowest Level in 25 Years, but Disparities still Exist

 

The use of tobacco products among middle and high school students in the United States has dropped to its lowest level in 25 years, according to data released by the 2024 National Youth Tobacco Survey (NYTS). In the past year alone, at least 500,000 fewer students are using tobacco products.

 

In 2024, approximately 2.25 million middle and high school students reported using at least one tobacco product in the past 30 days, compared to 2.8 million in 2023. A significant decrease in e-cigarette use is the main factor for this decline, with 2.13 million adolescents using e-cigarettes in 2023 compared to 1.63 million in 2024. Cigarette use also reached its lowest level in survey history, with only 1.4% of students reporting current use in 2024.

 

Progress varies among different groups. Between 2023 and 2024, there was a significant decrease in the use of tobacco products, e-cigarettes, and various tobacco products among female students. Hispanic students also showed a downward trend during the same period. However, among non-Hispanic American Indian or Alaska Native students, the use of various tobacco products has increased, and non-Hispanic white students have also seen an increase in the use of nicotine pouches.

 

PATH Study: Release of the 7th Wave of PATH Study Biomarker Data File

 

The Food and Drug Administration's Center for Tobacco Products and the National Institute on Drug Abuse, a subsidiary of the National Institutes of Health, have released the seventh wave of the Biomarker Restricted Use Files (BRUF) collected between January 2022 and April 2023. Researchers can apply to access this data. This is the first time the seventh wave of biomarker data files has been included.

 

The first wave of sample data was also expanded to include adults who had previously experimented with or used tobacco products long-term.

 

FDA is Set to Hold a Large-scale Online Seminar on PATH Study

 

On January 9, 2025, the FDA will discuss key findings from the Population Assessment of Tobacco and Health (PATH) study in a web seminar. Over the past decade, this longitudinal study has tracked significant changes in tobacco product use, including the sharp increase and decrease in e-cigarette use, the emergence of new products such as nicotine pouches, and the growing concern about the concurrent use of multiple tobacco products. The seminar will provide an overview of the PATH study, highlighting how the scientific evidence it has generated guides FDA regulatory activities and public health efforts.

 

In recent comments and public meetings, leaders of the NIH and FDA have called for innovative smoking cessation treatments.

 

Leaders from the FDA and NIH have published a new commentary in the Annals of Internal Medicine, calling for innovative approaches in the development of smoking cessation treatments. The article emphasizes the need for active participation in smoking cessation research from stakeholders including clinicians, academia, industry, public health, and patient advocacy groups. Discussions and recommendations are made to promote research and development of smoking cessation therapies, with a focus on studying the long-term health effects of e-cigarettes and their toxicology. Furthermore, the FDA and NIH held a public meeting in October titled "Advancing Tobacco Cessation: Priorities for FDA and NIH," which focused on the development of innovative smoking cessation products to assist both adults and youth. The public comment period has been extended until December 20, 2024, allowing the public to share insights, data, and recommendations on advancing innovative smoking cessation products and therapies to help youth and adults.

 

FDA Issues Regulatory Science Policy Memorandum Related to Pre-market Application Review

 

In November of this year, the FDA released additional regulatory science policy memoranda related to premarket application reviews by the agency. This release included 13 memoranda from 2020 to 2023, outlining processes and prioritization methods for filing and reviewing premarket tobacco product applications (PMTAs) for flavored e-cigarettes and other products, as well as the basis for specific actions supporting environmental assessments. These scientific policy memoranda provide the FDA's views on specific topics at particular points in time, which may be updated due to policy changes.

 

In April, the FDA resumed the release of regulatory science policy memoranda. This is the fourth batch of memoranda released in 2024, including the one released today, bringing the total number of memoranda released by the FDA to 26.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Canada Recalls Nearly 25,000 GTMBAR Vapes Over Child-Resistant Packaging Violations; Brand Linked to Shenzhen GTM Bar, with LK Vape as Importer and Distributor
Canada Recalls Nearly 25,000 GTMBAR Vapes Over Child-Resistant Packaging Violations; Brand Linked to Shenzhen GTM Bar, with LK Vape as Importer and Distributor
Health Canada announced a recall of 24,950 China-made GTMBAR 45K disposable vaping devices on November 13, 2026, citing non-compliance with child-resistant packaging requirements. The devices were sold in Canada between December 2024 and October 2026 and feature a 20mL e-liquid system with a nicotine concentration of 20 mg/mL. No related incidents or injuries had been reported as of November 12. Quebec-based LK Vape is the Canadian importer and distributor, while Shenzhen GTM bar Electronic Technology Co., Ltd. holds the GTMBAR trademark registration in the United Kingdom.
Regulations
Nov.16
How Investors Are Repricing the Global Tobacco Industry as Nicotine Markets Shift
How Investors Are Repricing the Global Tobacco Industry as Nicotine Markets Shift
How are investors reassessing the global tobacco industry as nicotine markets evolve? In an interview with 2Firsts, Charlie Chen, Head of Research at CCB International Securities, forecasts annual growth of 30–50% for nicotine pouches, outpacing vaping and heated tobacco. He examines how regulatory enforcement, shifting market shares and new business models are influencing company valuations. The report also explores differences between multinational tobacco groups and Chinese companies, drawing on insights from the New Approaches Summit on profitability, investment strategies and industry consolidation.
Nov.11
FDA Unifies Tobacco Registration and Product Listing Form Across Product Categories
FDA Unifies Tobacco Registration and Product Listing Form Across Product Categories
The U.S. FDA has consolidated two tobacco establishment registration and product listing forms into a redesigned Form FDA 3741 covering all regulated product categories, including e-cigarettes, heated tobacco products and nicotine pouches. The current requirements remain limited to domestic establishments. Separately, the FDA has proposed extending registration and product listing requirements to foreign manufacturers, signaling greater regulatory attention to manufacturing entities and product-level information across the tobacco and nicotine supply chain.
FDA
Sep.30
UK Extends Age-18 Rules to Zero-Nicotine Vapes and Nicotine Pouches From Oct. 29, Bans Vending Machines and Promotional Giveaways
UK Extends Age-18 Rules to Zero-Nicotine Vapes and Nicotine Pouches From Oct. 29, Bans Vending Machines and Promotional Giveaways
Key provisions of the UK's Tobacco and Vapes Act 2026 will take effect on Oct. 29, extending an age-18 sales restriction to all vaping and non-medicinal nicotine products. In England, Wales and Northern Ireland, the change brings zero-nicotine vapes within statutory age-of-sale rules and also covers products including nicotine pouches, strips and pearls. The law will also prohibit proxy purchasing for under-18s, consumer-facing vending machines, promotional giveaways and substantial discounts intended to promote vaping and nicotine products.
Regulations
Oct.10
GAO Audit Finds Nearly 132,000 FDA Tobacco Applications Waiting an Average 1,266 Days as Nicotine Pouch Pilot Practices Move Into Vape PMTA Reviews
GAO Audit Finds Nearly 132,000 FDA Tobacco Applications Waiting an Average 1,266 Days as Nicotine Pouch Pilot Practices Move Into Vape PMTA Reviews
A U.S. Government Accountability Office audit found that 131,915 tobacco product applications submitted to the FDA since 2018 remained without a final review as of December 31, 2025, with pending applications waiting an average of 1,266 days. GAO also found FDA lacks the data needed to systematically determine whether scientific reviews meet applicable timelines. HHS agreed to upgrade the agency's tracking systems. At the same time, FDA has begun applying lessons from its nicotine pouch PMTA pilot to e-cigarette reviews, while changes to enforcement policy and electronic submissions are making the specific stage of a PMTA increasingly relevant to market access.
FDA
Oct.03
PMI Launches Fourth IQOS Convenience-Store Discount of 2026 for Black Friday in Japan, Cutting ILUMA i ONE to About $19 After Ploom AURA Fell to About $9
PMI Launches Fourth IQOS Convenience-Store Discount of 2026 for Black Friday in Japan, Cutting ILUMA i ONE to About $19 After Ploom AURA Fell to About $9
Philip Morris Japan launched its fourth confirmed nationwide convenience-store discount campaign for IQOS ILUMA i devices in 2026 on October 26, cutting three models by as much as ¥2,000, or about $12.70. The campaign began one day after JT ended a promotion that reduced Ploom AURA to ¥1,480, or about $9.40. JT says Ploom's share of Japan's heated-products category rose from 10.9% in January 2024 to 18.3% in June 2026, a gain of 7.4 percentage points, while PMI says IQOS still held about 68% category share in the third quarter. At the same time, Japan's two-stage heated-tobacco tax adjustment has pushed stick prices higher, leaving device discounts as an increasingly important tool for lowering the upfront cost of customer acquisition.
Market
Oct.28